In this interview, recorded at the Myeloma 2017 meeting in Edinburgh, UK, Ashutosh Wechalekar, MBBS, MD, FRCP, FRCPath, DM, from University College London, London, UK, talks to us about the most anticipated upcoming trial results in the treatment of amyloidosis to be released at ASH 2017, including genetic data exploring the effect of translocations such as t(11;14) upon a patients response to bortezomib, and the addition of bortezomib to a combined therapy regimen of melphalan and dexamethasone.
Upcoming amyloidosis clinical trial data to look forward to at ASH 2017
